Cargando…
A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer
Purpose: The aim of this study was to compare the pharmacokinetics and safety between two vinorelbine formulations [a new oil-in-water emulsion formulation (ANX) versus a previously marketed solution formulation (Navelbine)] in Chinese patients with advanced non-small cell lung cancer (NSCLC). Metho...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637297/ https://www.ncbi.nlm.nih.gov/pubmed/31354489 http://dx.doi.org/10.3389/fphar.2019.00774 |
_version_ | 1783436214027681792 |
---|---|
author | Wu, Guolan Wu, Lihua Zhou, Huili Lin, Meihua Peng, Ling Wang, Yina Zhai, You Hu, Xingjiang Zheng, Yunliang Lv, Duo Liu, Jian Shentu, Jianzhong |
author_facet | Wu, Guolan Wu, Lihua Zhou, Huili Lin, Meihua Peng, Ling Wang, Yina Zhai, You Hu, Xingjiang Zheng, Yunliang Lv, Duo Liu, Jian Shentu, Jianzhong |
author_sort | Wu, Guolan |
collection | PubMed |
description | Purpose: The aim of this study was to compare the pharmacokinetics and safety between two vinorelbine formulations [a new oil-in-water emulsion formulation (ANX) versus a previously marketed solution formulation (Navelbine)] in Chinese patients with advanced non-small cell lung cancer (NSCLC). Method: This was a single-center, randomized, open-label study. Eligible patients aged 18–70 years who had histologically or cytologically confirmed NSCLC were enrolled. In cycle 1, the patients alternatively received the two formulations (30 mg/m(2), given as a 10-min infusion) with a 7-day interval. Samples for pharmacokinetic analysis were taken during cycle 1. For all subsequent 21-day cycles (maximum four cycles), ANX was administered on days 1 and day 8. Bioequivalence analysis was performed on C(max), AUC(last), and AUC(inf). The safety profiles and anti-tumor effects were also determined. Results: From March 2013 to January 2015, 24 patients were enrolled and 20 were eligible for pharmacokinetic evaluation. The 20 subjects in the pharmacokinetic analysis set had a median age of 61 years (range, 37–70 years), and 15 patients were male (75%). Mean vinorelbine C(max) values for ANX and Navelbine were 1,317.40 and 1,446.30 ng/mL, respectively. Corresponding AUC(last )values were 797.08 and 924.26 ng·h/mL, respectively. AUC(inf )values were 830.14 and 957.16 ng·h/mL, respectively. Treatment ratios of the geometric means were 90.00% (90% CI, 83.22–99.07%) for C(max), 86.92% (90% CI, 80.91–93.37%) for AUC(last), and 87.44% (90% CI, 82.08–93.16%) for AUC(inf). These results met the required 80–125% bioequivalence criteria. The most frequently reported adverse events after vinorelbine administration were neutropenia, leucopenia, neutropenic fever, and constipation. Conclusion: At therapeutic dosage levels, pharmacokinetic behavior and safety profiles were similar for both formulations. Chinese National Registry Code: ChiCTR-IPR-15005856. |
format | Online Article Text |
id | pubmed-6637297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66372972019-07-26 A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer Wu, Guolan Wu, Lihua Zhou, Huili Lin, Meihua Peng, Ling Wang, Yina Zhai, You Hu, Xingjiang Zheng, Yunliang Lv, Duo Liu, Jian Shentu, Jianzhong Front Pharmacol Pharmacology Purpose: The aim of this study was to compare the pharmacokinetics and safety between two vinorelbine formulations [a new oil-in-water emulsion formulation (ANX) versus a previously marketed solution formulation (Navelbine)] in Chinese patients with advanced non-small cell lung cancer (NSCLC). Method: This was a single-center, randomized, open-label study. Eligible patients aged 18–70 years who had histologically or cytologically confirmed NSCLC were enrolled. In cycle 1, the patients alternatively received the two formulations (30 mg/m(2), given as a 10-min infusion) with a 7-day interval. Samples for pharmacokinetic analysis were taken during cycle 1. For all subsequent 21-day cycles (maximum four cycles), ANX was administered on days 1 and day 8. Bioequivalence analysis was performed on C(max), AUC(last), and AUC(inf). The safety profiles and anti-tumor effects were also determined. Results: From March 2013 to January 2015, 24 patients were enrolled and 20 were eligible for pharmacokinetic evaluation. The 20 subjects in the pharmacokinetic analysis set had a median age of 61 years (range, 37–70 years), and 15 patients were male (75%). Mean vinorelbine C(max) values for ANX and Navelbine were 1,317.40 and 1,446.30 ng/mL, respectively. Corresponding AUC(last )values were 797.08 and 924.26 ng·h/mL, respectively. AUC(inf )values were 830.14 and 957.16 ng·h/mL, respectively. Treatment ratios of the geometric means were 90.00% (90% CI, 83.22–99.07%) for C(max), 86.92% (90% CI, 80.91–93.37%) for AUC(last), and 87.44% (90% CI, 82.08–93.16%) for AUC(inf). These results met the required 80–125% bioequivalence criteria. The most frequently reported adverse events after vinorelbine administration were neutropenia, leucopenia, neutropenic fever, and constipation. Conclusion: At therapeutic dosage levels, pharmacokinetic behavior and safety profiles were similar for both formulations. Chinese National Registry Code: ChiCTR-IPR-15005856. Frontiers Media S.A. 2019-07-11 /pmc/articles/PMC6637297/ /pubmed/31354489 http://dx.doi.org/10.3389/fphar.2019.00774 Text en Copyright © 2019 Wu, Wu, Zhou, Lin, Peng, Wang, Zhai, Hu, Zheng, Lv, Liu and Shentu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wu, Guolan Wu, Lihua Zhou, Huili Lin, Meihua Peng, Ling Wang, Yina Zhai, You Hu, Xingjiang Zheng, Yunliang Lv, Duo Liu, Jian Shentu, Jianzhong A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer |
title | A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer |
title_full | A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer |
title_fullStr | A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer |
title_full_unstemmed | A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer |
title_short | A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer |
title_sort | phase i comparative pharmacokinetic and safety study of two intravenous formulations of vinorelbine in patients with advanced non-small cell lung cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637297/ https://www.ncbi.nlm.nih.gov/pubmed/31354489 http://dx.doi.org/10.3389/fphar.2019.00774 |
work_keys_str_mv | AT wuguolan aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT wulihua aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT zhouhuili aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT linmeihua aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT pengling aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT wangyina aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT zhaiyou aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT huxingjiang aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT zhengyunliang aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT lvduo aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT liujian aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT shentujianzhong aphaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT wuguolan phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT wulihua phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT zhouhuili phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT linmeihua phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT pengling phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT wangyina phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT zhaiyou phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT huxingjiang phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT zhengyunliang phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT lvduo phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT liujian phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer AT shentujianzhong phaseicomparativepharmacokineticandsafetystudyoftwointravenousformulationsofvinorelbineinpatientswithadvancednonsmallcelllungcancer |